SCNX Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.…
Industry Peers
Pharmaceutical RetailersKey Statistics
About Scienture Holdings (NASDAQ: SCNX)
›
Scienture Holdings (NASDAQ: SCNX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Pharmaceutical Retailers industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 2.435 USD on 19 November 2026, down 87.6% over 52 weeks. Its 52-week range is 2.240 USD to 19.48 USD: the price is 87.5% below the high and 8.7% above the low.
Its market capitalisation is 4.35M USD.
Scienture Holdings reports return on equity of -59.2%.
Its debt exceeds its cash by 2.50M USD, a debt-to-equity ratio of 0.00. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 6.000 USD is 146.4% above the current price.